Regeneron Reports Third Quarter 2009 Financial and Operati...(Total assets $7...),Health

Date:11/3/2009

Total assets $742,192 $724,220 ======== ======== LIABILITIES AND STOCKHOLDERS' EQUITY Accounts payable and accrued expenses $55,291 $36,168 Deferred revenue 198,546 209,925 Facility lease obligation 62,571 54,182 Other long-term liabilities 3,341 2,431 Stockholders' equity 422,443 421,514 ------- ------- Total liabilities and stockholders' equity $742,192 $724,220 ======== ======== * Revised as described in the paragraph of this press release titled "Revision of Previously Issued Financial Statements." REGENERON PHARMACEUTICALS, INC. CONDENSED STATEMENTS OF OPERATIONS (Unaudited) (In thousands, except per share data) For the three months For the nine months ended September 30, ended September 30, 2009 2008 2009 2008 ---- ---- ---- ---- (Revised)* (Revised)* Revenues Contract research and development $82,482 $52,878 $219,104 $149,914 Research progress payments 20,000 20,000 Technology licensing 10,000 10,000 30,000 30,000 Net product sales 4,973 2,706 13,364 2,706 ----- ----- ------ ----- 117,455 65,584 282,468 182,620
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. Spherix Reports Second Quarter Earnings
7. Tapestry Reports Second Quarter 2007 Results
8. Callisto Reports on Second-Quarter 2007 Milestones
9. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress